Company Overview and News
Stop missing out on important events!
CombiMatrix Corp. (NASDAQ:CBMX) has 17 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,611,160 shares. Largest shareholders include Acuta Capital Partners, Llc, Frigate Ventures LP, MMCAP International Inc. SPC, Renaissance Technologies LLC, Deutsche Bank Ag\, Stonepine Capital Management, LLC, Bridgeway Capital Management Inc, Asymmetry Capital Management, L. (6-0)
Stonepine Capital Management, LLC has disclosed 22 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 167,888,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Stonepine Capital Management, LLC's top holdings are Viveve Medical, Inc. (OTC:VIVMF) , Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) , Pacira Pharmaceuticals, Inc. (78-4)
The deal is very small with a total value of roughly $33MM, which will lead to very little institutional attention. (20-3)
* Combimatrix Corp says approximately 1.79 million of common shares voting in meeting voted in favor of approval & adoption of all-stock merger agreement Source text for Eikon: Further company coverage: (20-0)
SAN FRANCISCO, July 31, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced two acquisitions to establish a leading position in family health genetic information services. Invitae has entered into a definitive agreement to acquire privately held Good Start Genetics, a molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders.
-- Good Start Genetics Provides Best-in-Class Carrier and NGS Preimplantation Screening to Leading IVF Centers -- -- CombiMatrix Trusted for Advanced DNA Diagnostics by Reproductive Health and Pediatric Specialists -- -- Invitae to Host Webcast for Investors on August 1 at 8 am ET / 5 am PT --
According to a new market research report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", published by MarketsandMarkets™, the Global Preimplantation Genetic Testing Market is projected to reach USD 541.